Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Editorial

FGFR1 amplification and the progression of non-invasive to invasive breast cancer

Alejandro A Gru* and D Craig Allred

Author Affiliations

Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

For all author emails, please log on.

Breast Cancer Research 2012, 14:116  doi:10.1186/bcr3340


See related research by Jang et al., http://breast-cancer-research.com/content/14/4/R115

Published: 14 November 2012

Abstract

The incidence of invasive breast cancer (IBC) can be dramatically reduced by improving our abilities to detect and treat ductal carcinoma in situ (DCIS). Progress will be based on a detailed understanding of molecular mechanisms responsible for tumor progression. An interesting study by Jang and colleagues evaluated and compared the frequency of amplification of four oncogenes (HER2, c-MYC, CCND1 and FGFR1) in large cohorts of pure DCIS, in the DCIS component of IBC, and in corresponding IBC. Of particular interest, they found a twofold increase in FGFR1 amplification in IBC versus pure DCIS, and significantly reduced disease-free survival in amplified versus unamplified IBC - leading the authors to conclude that FGFR1 plays an important role in the development and progression of IBC. These observations indeed provide hints that FGFR1 is important in this setting, although the issue is very complex and far from resolved.